JAZZ
Bearish signalScored 2026-10-12 Drivers: Congress, trend, fundamentals. Insiders: neutral. Moteurs : Congrès, tendance, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Jazz Pharmaceuticals plc
- Nom
- Jazz Pharmaceuticals plc
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $13.9B
- Employés
- 2,890
- PDG
- Renee D. Gala
- Site web
- https://www.jazzpharma.com
- Marché
- GMABHRMYINCYLEGNLGNDMGNX
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 14 000 titres (~3 355 560,00 $ US)
- Insiders
- GALA RENEE DCOZADD BRUCE C
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$5,724,456
Avg sell (VWAP, 90d window) $243.59 vs last close $210.23 (-13.7%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$5,724,456 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-06
- Liquidity
- Liquid $170,394,610/day · 20d vol
- Last synced
-
2026-10-17 09:40:32
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-06 | GALA RENEE D | Sell · S · 10b5-1 | 2,000 | $236.40 | $472,800 | Form 4 |
| 2026-10-01 | COZADD BRUCE C | Sell · S · 10b5-1 | 6,000 | $230.33 | $1,381,980 | Form 4 |
| 2026-09-10 | Patil Neena M | Sell · S · 10b5-1 | 1,200 | $240.94 | $289,128 | Form 4 |
| 2026-09-08 | GALA RENEE D | Sell · S · 10b5-1 | 2,000 | $243.03 | $486,060 | Form 4 |
| 2026-09-01 | COZADD BRUCE C | Sell · S · 10b5-1 | 6,000 | $250.13 | $1,500,780 | Form 4 |
| 2026-08-27 | Iannone Robert | Sell · S · 10b5-1 | 300 | $252.76 | $75,828 | Form 4 |
| 2026-08-03 | COZADD BRUCE C | Sell · S · 10b5-1 | 6,000 | $252.98 | $1,517,880 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2023-07-12 | Daniel Goldman | Sale (Full) | $15,001 - $50,000 |
| 2023-05-19 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-03-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-03-06 | Daniel Goldman | Purchase | $15,001 - $50,000 |
| 2023-01-31 | Daniel Goldman | Sale (Full) | $1,001 - $15,000 |
| 2022-09-26 | Thomas Suozzi | Sale (Full) | $1,001 - $15,000 |
| 2021-10-19 | Thomas Suozzi | Purchase | $1,001 - $15,000 |
| 2019-07-15 | Bill Flores | Purchase | $15,001 - $50,000 |
| 2018-08-28 | Carlos Curbelo | Purchase | $1,001 - $15,000 |
Signal
Bearish signalScored 2026-10-12 Drivers: Congress, trend, fundamentals. Insiders: neutral. Moteurs : Congrès, tendance, fondamentaux. Initiés : neutre.
JAZZ presents a deeply stressed financial profile with collapsing EBITDA margins, a debt-to-EBITDA ratio of 15.3x, and a shift to net losses in 2025, making the balance sheet a primary concern.
The first sentence of the analysis written for JAZZ on 2026-10-12 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $5.7M) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $5.7M) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Supports a bullish reading. 2 purchase disclosures year to date
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 1.86 · operating margin 5.3%
Suggested stop 172.72, nearest stored support minus 0.5 ATR(17.8% under the last close). Reward/risk to the next stored resistance is 0.82. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 88.2% | 89.0% | 88.6% | 85.2% | 85.8% | |
| Ebit Margin | -10.2% | 21.2% | 21.1% | 22.9% | 15.4% | |
| Ebitda Margin | 6.2% | 37.4% | 37.8% | 40.1% | 33.2% | |
| Operating Profit Margin | 5.3% | 17.6% | 15.1% | -1.8% | 5.5% | |
| Pretax Profit Margin | -14.7% | 11.5% | 7.7% | -10.5% | -3.7% | |
| Continuous Operations Profit Margin | -8.3% | 13.8% | 10.8% | -6.1% | -10.7% | |
| Net Profit Margin | -8.3% | 13.8% | 10.8% | -6.1% | -10.6% | |
| Bottom Line Profit Margin | -8.3% | 14.0% | 11.5% | -6.1% | -10.7% | |
| Current Ratio | 1.858 | 4.457 | 2.236 | 2.793 | 3.227 | |
| Quick Ratio | 1.672 | 3.995 | 1.847 | 2.028 | 1.901 | |
| Solvency Ratio | 0.046 | 0.154 | 0.138 | 0.052 | 0.027 | |
| Cash Ratio | 0.621 | 2.323 | 0.980 | 0.945 | 0.731 | |
| Price To Earnings Ratio | -29.110 | 13.593 | 18.779 | -44.500 | -23.122 | |
| Price To Earnings Growth Ratio | 0.177 | 0.355 | -0.066 | 1.270 | 0.101 | |
| Forward Price To Earnings Growth Ratio | 0.177 | 0.355 | -0.066 | 1.270 | 0.101 | |
| Price To Earnings Diluted Ratio | -29.110 | 14.237 | 20.164 | -44.500 | -23.122 | |
| Price To Earnings Diluted Growth Ratio | 0.174 | 0.341 | -0.075 | 1.270 | 0.100 | |
| Price To Book Ratio | 2.401 | 1.860 | 2.083 | 3.229 | 1.918 | |
| Price To Sales Ratio | 2.429 | 1.872 | 2.030 | 2.723 | 2.458 | |
| Price To Free Cash Flow Ratio | 9.046 | 5.650 | 7.289 | 12.876 | 10.376 | |
| Price To Operating Cash Flow Ratio | 7.647 | 5.455 | 7.129 | 7.833 | 9.769 | |
| Debt To Assets Ratio | 0.465 | 0.513 | 0.508 | 0.536 | 0.500 | |
| Debt To Equity Ratio | 1.256 | 1.505 | 1.550 | 1.884 | 1.552 | |
| Debt To Capital Ratio | 0.557 | 0.601 | 0.608 | 0.653 | 0.608 | |
| Long Term Debt To Capital Ratio | 0.501 | 0.598 | 0.578 | 0.649 | 0.603 | |
| Financial Leverage Ratio | 2.700 | 2.934 | 3.049 | 3.511 | 3.102 | |
| Working Capital Turnover Ratio | 1.548 | 1.483 | 2.147 | 2.106 | 1.552 | |
| Operating Cash Flow Ratio | 0.605 | 1.344 | 0.711 | 1.363 | 0.962 | |
| Operating Cash Flow Sales Ratio | 0.318 | 0.343 | 0.285 | 0.348 | 0.252 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.845 | 0.966 | 0.978 | 0.608 | 0.942 | |
| Debt Service Coverage Ratio | 0.437 | 5.995 | 1.755 | 5.097 | 2.620 | |
| Interest Coverage Ratio | 1.151 | 3.010 | 1.999 | -0.227 | 0.611 | |
| Short Term Operating Cash Flow Coverage Ratio | 1.316 | 45.029 | 1.805 | 41.032 | 25.113 | |
| Operating Cash Flow Coverage Ratio | 0.250 | 0.227 | 0.189 | 0.219 | 0.127 | |
| Capital Expenditure Coverage Ratio | 6.464 | 29.039 | 45.572 | 2.553 | 17.098 | |
| Dividend Paid And Capex Coverage Ratio | 6.464 | 29.039 | 45.572 | 2.553 | 17.098 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 54.801 | 7.468 | 8.328 | 10.141 | 12.811 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 88.2% | ▼-0.8% | ▲0.8% |
| Ebit Margin | -10.2% | ▼-31.3% | ▼-24.2% |
| Ebitda Margin | 6.2% | ▼-31.2% | ▼-24.8% |
| Operating Profit Margin | 5.3% | ▼-12.3% | ▼-3.1% |
| Pretax Profit Margin | -14.7% | ▼-26.2% | ▼-12.8% |
| Continuous Operations Profit Margin | -8.3% | ▼-22.1% | ▼-8.2% |
| Net Profit Margin | -8.3% | ▼-22.1% | ▼-8.2% |
| Bottom Line Profit Margin | -8.3% | ▼-22.4% | ▼-8.4% |
| Current Ratio | 1.858 | ▼-2.599 | ▼-1.056 |
| Quick Ratio | 1.672 | ▼-2.323 | ▼-0.617 |
| Solvency Ratio | 0.046 | ▼-0.108 | ▼-0.037 |
| Cash Ratio | 0.621 | ▼-1.703 | ▼-0.499 |
| Price To Earnings Ratio | -29.110 | ▼-42.702 | ▼-16.238 |
| Price To Earnings Growth Ratio | 0.177 | ▼-0.178 | ▼-0.190 |
| Forward Price To Earnings Growth Ratio | 0.177 | ▼-0.178 | ▼-0.190 |
| Price To Earnings Diluted Ratio | -29.110 | ▼-43.347 | ▼-16.643 |
| Price To Earnings Diluted Growth Ratio | 0.174 | ▼-0.167 | ▼-0.188 |
| Price To Book Ratio | 2.401 | ▲0.540 | ▲0.102 |
| Price To Sales Ratio | 2.429 | ▲0.558 | ▲0.127 |
| Price To Free Cash Flow Ratio | 9.046 | ▲3.396 | ▼-0.001 |
| Price To Operating Cash Flow Ratio | 7.647 | ▲2.191 | ▲0.080 |
| Debt To Assets Ratio | 0.465 | ▼-0.048 | ▼-0.040 |
| Debt To Equity Ratio | 1.256 | ▼-0.249 | ▼-0.293 |
| Debt To Capital Ratio | 0.557 | ▼-0.044 | ▼-0.049 |
| Long Term Debt To Capital Ratio | 0.501 | ▼-0.097 | ▼-0.085 |
| Financial Leverage Ratio | 2.700 | ▼-0.234 | ▼-0.359 |
| Working Capital Turnover Ratio | 1.548 | ▲0.065 | ▼-0.219 |
| Operating Cash Flow Ratio | 0.605 | ▼-0.740 | ▼-0.392 |
| Operating Cash Flow Sales Ratio | 0.318 | ▼-0.025 | ▲0.009 |
| Free Cash Flow Operating Cash Flow Ratio | 0.845 | ▼-0.120 | ▼-0.022 |
| Debt Service Coverage Ratio | 0.437 | ▼-5.558 | ▼-2.744 |
| Interest Coverage Ratio | 1.151 | ▼-1.859 | ▼-0.158 |
| Short Term Operating Cash Flow Coverage Ratio | 1.316 | ▼-43.713 | ▼-21.543 |
| Operating Cash Flow Coverage Ratio | 0.250 | ▲0.023 | ▲0.048 |
| Capital Expenditure Coverage Ratio | 6.464 | ▼-22.575 | ▼-13.682 |
| Dividend Paid And Capex Coverage Ratio | 6.464 | ▼-22.575 | ▼-13.682 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 54.801 | ▲47.332 | ▲36.091 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $10.37B | $7.62B | $7.78B | $9.96B | $7.61B | |
| Enterprise value | $14.40B | $11.36B | $12.07B | $14.89B | $13.17B | |
| EV / Sales | 3.37x | 2.79x | 3.15x | 4.07x | 4.25x | |
| EV / Op. cash flow | 10.62x | 8.14x | 11.05x | 11.71x | 16.91x | |
| EV / Free cash flow | 12.56x | 8.43x | 11.30x | 19.25x | 17.96x | |
| EV / EBITDA | 54.80x | 7.47x | 8.33x | 10.14x | 12.81x | |
| Net debt / EBITDA | 15.35x | 2.46x | 2.96x | 3.36x | 5.41x | |
| Current ratio | 1.86x | 4.46x | 2.24x | 2.79x | 3.23x | |
| Income quality | -3.81x | 2.49x | 2.63x | -5.68x | -2.36x | |
| Graham number | — | $116 | $93 | — | — | |
| Graham net-net | -$67 | -$67 | -$82 | -$96 | -$114 | |
| Tax burden | 56.7% | 119.5% | 140.7% | 58.5% | 289.7% | |
| Interest burden | 145.0% | 54.4% | 36.4% | -45.6% | -23.9% | |
| Working capital | $1.92B | $3.59B | $1.90B | $1.67B | $1.80B | |
| Invested capital | $8.44B | $10.29B | $9.30B | $9.46B | $11.13B | |
| Return on assets | -3.1% | 4.7% | 3.6% | -2.1% | -2.7% | |
| Operating ROA | 1.9% | 6.1% | 5.2% | -0.6% | 1.8% | |
| Return on tangible assets | -6.6% | 10.1% | 9.8% | -6.7% | -9.9% | |
| Return on equity | -8.2% | 13.7% | 11.1% | -7.3% | -8.3% | |
| Return on invested capital | 1.2% | 6.5% | 5.5% | -0.4% | 1.5% | |
| Return on capital employed | 2.4% | 6.5% | 5.9% | -0.7% | 1.5% | |
| Earnings yield | -3.4% | 7.4% | 5.3% | -2.2% | -4.3% | |
| Free cash flow yield | 11.1% | 17.7% | 13.7% | 7.8% | 9.6% | |
| Capex / Op. cash flow | 15.5% | 3.4% | 2.2% | 39.2% | 5.8% | |
| Capex / Depreciation | 30.1% | 7.3% | 3.8% | 79.1% | 8.2% | |
| Capex / Sales | 4.9% | 1.2% | 0.6% | 13.6% | 1.5% | |
| SG&A / Sales | 42.4% | 34.0% | 35.0% | 38.7% | 46.9% | |
| R&D / Sales | 18.3% | 21.7% | 22.2% | 16.1% | 16.3% | |
| Stock comp / Sales | 6.8% | 6.1% | 5.9% | 6.1% | 6.1% | |
| Intangibles / Total assets | 53.7% | 53.9% | 62.9% | 69.1% | 73.0% | |
| Days sales outstanding | 71d | 64d | 67d | 65d | 66d | |
| Days payables outstanding | 89d | 64d | 86d | 61d | 83d | |
| Operating cycle | 373d | 458d | 567d | 547d | 955d | |
| Cash conversion cycle | 285d | 394d | 481d | 486d | 872d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-06 Here''s Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here''s why you should take advantage.
- 2026-10-05 Financial Comparison: Jazz Pharmaceuticals (NASDAQ:JAZZ) vs. vTv Therapeutics (NASDAQ:VTVT) Jazz Pharmaceuticals (NASDAQ: JAZZ - Get Free Report) and vTv Therapeutics (NASDAQ: VTVT - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, valuation, profitability, dividends and institutional ownership. Analyst Ratings This is a summary of current
- 2026-09-21 Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands Jazz Pharmaceuticals (NASDAQ: JAZZ) outlined development and commercial plans for its oncology, epilepsy and sleep franchises during a discussion with Deutsche Bank analyst David Hoang, emphasizing the expansion potential of HER2-targeted therapy Ziihera and ongoing lifecycle work for EPIDIOLEX. Ziihera Data and Development Plans An unnamed Jazz executive said zanidatamab, marketed as Ziihera, produced a statistically
- 2026-09-21 Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B Jazz Pharmaceuticals (NASDAQ: JAZZ) executives outlined the company''s oncology growth strategy, early commercial progress for recently launched therapies and business-development priorities during the Morgan Stanley Global Healthcare Conference. Chumi Khurana, senior vice president of U.S. Oncology Franchise, said Jazz''s oncology business grew revenue 32% year over year and crossed the $1 billion mark in 2025. She
- 2026-09-20 Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B Jazz Pharmaceuticals NASDAQ: JAZZ executives outlined the company''s oncology growth strategy, early commercial progress for recently launched therapies and business-development priorities during the Morgan Stanley Global Healthcare Conference.
- 2026-09-20 Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands Jazz Pharmaceuticals NASDAQ: JAZZ outlined development and commercial plans for its oncology, epilepsy and sleep franchises during a discussion with Deutsche Bank analyst David Hoang, emphasizing the expansion potential of HER2-targeted therapy Ziihera and ongoing lifecycle work for EPIDIOLEX. Get Jazz Pharmaceuticals alerts:Sign UpZiihera Data and Development Plans An unnamed Jazz executive said zanidatamab, marketed as Ziihera, produced a statistically significant overall-survival result for its zanidatamab-plus-chemotherapy arm versus a control arm in a second interim analysis.
- 2026-09-18 Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition? Jazz paid $820 million up front to acquire Actio Biosciences. Actio shareholders could receive another $500 million in milestone payments.
- 2026-09-17 Engineers Gate Manager LP Reduces Stock Position in Jazz Pharmaceuticals PLC $JAZZ Engineers Gate Manager LP cut its holdings in Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) by 93.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,287 shares of the specialty pharmaceutical company''s stock after selling 86,703 shares
- 2026-09-16 Jazz Pharmaceuticals plc (JAZZ) Presents at Deutsche Bank 2026 Healthcare Summit Transcript Jazz Pharmaceuticals plc (JAZZ) Presents at Deutsche Bank 2026 Healthcare Summit Transcript
- 2026-09-15 Jazz Pharmaceuticals plc (JAZZ) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Jazz Pharmaceuticals plc (JAZZ) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript